SCP
CTMX icon

Sender Company & Partners’s CytomX Therapeutics CTMX Stock Holding History

Sender Company & Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-40,720
Closed -$176K – 65
2021
Q4 		$176K Buy
+40,720
New +$239K 0.09% 92

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Sender Company & Partners's CTMX Position: Q1 2022 in Review

Sender Company & Partners sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 40,720 shares — an estimated $176K sold.

Sender Company & Partners first reported a position in CTMX in Q4 2021 and held it in 1 quarter. The position peaked at $176K in Q4 2021. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

  • Sender Company & Partners reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sender Company & Partners sold 40,720 CytomX Therapeutics shares in Q1 2022, an estimated $176K.
  • Sender Company & Partners first reported a position in CytomX Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sender Company & Partners's CytomX Therapeutics position peaked at $176K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Sender Company & Partners's 13F filing for Q1 2022, filed 17 May 2022.